Eli Lilly and Company (NYSE:LLY) Given New $1,230.00 Price Target at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised its price target on Eli Lilly to $1,230 (from $1,205) with an "overweight" rating, implying about a 26.3% upside from the prior close.
• Eli Lilly beat Q1 expectations with $8.55 EPS vs. $6.97 expected and revenue of $19.8B (up 55.5% YoY), and set FY26 guidance of 35.5–37.0 EPS, fueling recent analyst upgrades and stock strength.
• Analysts remain broadly positive (consensus "Moderate Buy" and average price target ~$1,218), but divergent calls and valuation concerns — including some downgrades — highlight sensitivity to continued GLP‑1 momentum.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price objective increased by stock analysts at Cantor Fitzgerald from $1,205.00 to $1,230.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage presently has an "overweight" rating on the stock. Cantor Fitzgerald's target price would indicate a potential upside of 26.32% from the stock's previous close.

LLY has been the topic of several other research reports. Leerink Partners lowered their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating on the stock in a research note on Monday. Freedom Capital raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 10th. Guggenheim raised their target price on shares of Eli Lilly and Company from $1,163.00 to $1,183.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Scotiabank reissued an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, HSBC cut shares of Eli Lilly and Company from a "hold" rating to a "reduce" rating and lowered their target price for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $1,218.30.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $39.12 during trading hours on Friday, hitting $973.72. 709,524 shares of the company traded hands, compared to its average volume of 3,150,024. The firm has a market cap of $919.99 billion, a P/E ratio of 42.62, a P/E/G ratio of 1.00 and a beta of 0.51. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm's 50-day simple moving average is $947.05 and its two-hundred day simple moving average is $984.98. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company's quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently made changes to their positions in the business. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares during the period. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. Finally, 10Elms LLP boosted its holdings in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares during the period. Institutional investors own 82.53% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly crushed Q1 estimates and raised full‑year guidance — strong GLP‑1 volume drove 56% revenue growth and management boosted FY26 revenue and EPS targets, a primary catalyst for the stock lift. Eli Lilly crushes Q1 estimates, raises full-year outlook
• Positive Sentiment: Foundayo oral GLP‑1 pill is already reaching patients (CEO: >20,000 prescriptions early), supporting upside to the obesity pill opportunity and long‑term GLP‑1 adoption. Lilly’s weight loss pill reaches brand new patients
• Positive Sentiment: FDA proposed excluding active ingredients for tirzepatide/semaglutide from bulk compounding — could limit cheaper compounded competitors and protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Market commentary and upgrades: analysts and investors upgraded/touted LLY after the print (Seeking Alpha upgrade, Guggenheim PT raise), reinforcing buy-side interest. Eli Lilly: Buying Opportunity (Rating Upgrade)
• Neutral Sentiment: Corporate activity supports pipeline expansion — acquisition of Ajax (JAK inhibitors) and a $2.25B AI/gene‑editing partnership broaden long‑term growth drivers but are multi‑year value creators. Why Eli Lilly is One of the Best Drug Stocks
• Neutral Sentiment: Summaries/transcripts of the earnings call and analyst notes provide color (Moby, Seeking Alpha transcript) for investors assessing sustainability of volume vs. pricing trends. Eli Lilly Q1 2026 Earnings Call Summary
• Negative Sentiment: Competition and mixed early pill metrics: social/industry notes point to a slower Foundayo launch vs. competitors in week‑to‑week scripts, and Novo remains a strong rival — this could cap near‑term share gains. Opinions on Foundayo Pill Launch
• Negative Sentiment: Valuation and selling activity: coverage notes call LLY an expensive stock even as some investors and insiders have been selling; high multiples raise sensitivity to any slowdown in GLP‑1 momentum. Valuation commentary from Gary Black

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.